Nurix Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Nurix Therapeutics, Inc. on May 19, 2025. The meeting was conducted virtually via live webcast. A quorum was established with 65,056,197 shares present, representing approximately 85.33% of the voting power.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on three proposals, all of which were approved:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2028 annual meeting.
- Judith A. Reinsdorf: 43,571,416 votes for; 17,651,464 votes withheld.
- Edward C. Saltzman: 50,302,518 votes for; 10,920,362 votes withheld.
- Roy D. Baynes: 60,821,712 votes for; 401,168 votes withheld.
- Proposal 2 (Ratification of Auditors): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending November 30, 2025.
- Votes For: 64,950,599
- Votes Against: 85,040
- Abstentions: 20,558
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on a non-binding advisory basis.
- Votes For: 49,788,975
- Votes Against: 11,341,365
- Abstentions: 92,540
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific terms of the executive compensation package approved in Proposal 3 by reviewing the definitive proxy statement filed on March 28, 2025.
- Confirm the tenure and background of the newly elected directors (Reinsdorf, Saltzman, Baynes) serving until 2028.
- Note the significant number of votes withheld for Judith A. Reinsdorf (approx. 28.7% of votes cast) compared to the other nominees.
- Review the full proxy statement for details on the "Broker Non-Votes" totaling 3,833,317 shares.